Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Holding ZVRA?
Track your performance easily
ZVRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.89 - $7.28
Previous Close$5.85
Volume536.41K
Average Volume (3M)257.07K
Market Cap
$244.84M
Enterprise Value$206.24M
Total Cash (Recent Filing)$83.43M
Total Debt (Recent Filing)$44.82M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 13, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding41,853,494
10 Day Avg. Volume180,992
30 Day Avg. Volume257,075
Standard Deviation1.33
R-Squared0.02
Alpha0.13
Financial Highlights & Ratios
Price to Book (P/B)2.71
Price to Sales (P/S)17.45
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.45
Enterprise Value/Gross Profit20.39
Enterprise Value/Ebitda-5.07
Forecast
1Y Price Target
$19.00Price Target Upside204.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Zevra Therapeutics News
PremiumCompany Announcements
Zevra Therapeutics Restructures to Focus on Rare Diseases
PremiumCompany Announcements
Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease
PremiumCompany Announcements
Zevra Therapeutics’ Transformative Third Quarter 2024
Bulls Say, Bears Say
Bulls Say
Financing And CapitalZevra announced that it entered into a $100M credit facility led by leading healthcare investors.
Product CompetitivenessOlpruva has come in at a discount to Ravicti and has easier dosing, which could make it highly competitive within the class.
Stock ValuationAnalyst believes the stock remains significantly undervalued as the company morphs into a rare disease-focused entity.
Bears Say
DebtZevra had to retire its existing debt of approximately $43M as part of the new financing transaction.
EarningsThe company's stock reacted negatively to a significant fourth-quarter earnings miss and restatement of previous financial results.
RevenueRevenue came in at $3.4mn vs. the expected $4.0mn.
---
Ownership Overview
20.12% Insiders
7.06% Mutual Funds
7.88% Other Institutional Investors
64.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZVRA FAQ
What was Zevra Therapeutics’s price range in the past 12 months?
Zevra Therapeutics lowest stock price was $3.89 and its highest was $7.28 in the past 12 months.
What is Zevra Therapeutics’s market cap?
Currently, no data Available
When is Zevra Therapeutics’s upcoming earnings report date?
Zevra Therapeutics’s upcoming earnings report date is Aug 13, 2024 which is 130 days ago.
How were Zevra Therapeutics’s earnings last quarter?
Zevra Therapeutics released its earnings results on May 08, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.467 by $0.067.
Is Zevra Therapeutics overvalued?
According to Wall Street analysts Zevra Therapeutics’s price is currently Undervalued.
Does Zevra Therapeutics pay dividends?
Zevra Therapeutics does not currently pay dividends.
What is Zevra Therapeutics’s EPS estimate?
Zevra Therapeutics’s EPS estimate is -$0.46.
How many shares outstanding does Zevra Therapeutics have?
Zevra Therapeutics has 41,853,493 shares outstanding.
What happened to Zevra Therapeutics’s price movement after its last earnings report?
Zevra Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.467. Following the earnings report the stock price went down -0.386%.
Which hedge fund is a major shareholder of Zevra Therapeutics?
Among the largest hedge funds holding Zevra Therapeutics’s share is Woodline Partners LP. It holds Zevra Therapeutics’s shares valued at 6M.
---
Zevra Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (204.98% Upside)
$19.00 (204.98% Upside)
Blogger Sentiment
Bullish
ZVRA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $58.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.38%
12-Months-Change
Fundamentals
Return on Equity
-84.68%
Trailing 12-Months
Asset Growth
41.92%
Trailing 12-Months
Company Description
Zevra Therapeutics
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
---
ZVRA Earnings Call
Q1 2024
0:00 / 0:00
---
ZVRA Stock 12 Month Forecast
Average Price Target
$19.00
▲(204.98% Upside)
Technical Analysis
Best Analysts Covering ZVRA
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+12.05%
reiterated a buy rating 8 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +12.05% per trade.
---